JuanCarlosVarelaMDPhD

Hematology • Orlando, FL

Hematologic Oncology

Physician

Join to view full profile

Dr. Varela is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Varela's full profile

Already have an account?

Office
1400 S Orange Ave
Orlando, FL 32806
Phone+1 321-841-2810

Fax+1 321-843-6330

Education & Training

Johns Hopkins UniversityResidency, Internal Medicine, 2010 - 2013
Medical University of South CarolinaClass of 2010

Certifications & Licensure

FL State Medical License 2017 - 2026
MA State Medical License 2022 - 2024
SC State Medical License 2015 - 2019
MD State Medical License 2012 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Publications & Presentations

PubMed

33 citations
The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies.
Lillian R. Neal, Bailey, Megan M. Wyatt, Jacob S. Bowers, Kinga Majchrzak
Journal of Immunology Research and Therapy. 2017-06-26
128 citations
Adoptive T cell immunotherapy for cancer.
Karlo Perica, Juan Carlos Varela, Mathias Oelke, Jonathan P. Schneck
Rambam Maimonides Medical Journal. 2015-01-29
22 citations
Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells
Christian Schütz, Juan Carlos Varela, Karlo Perica, Carl Haupt, Mathias Oelke
Oncotarget. 2016-09-01

Journal Articles

Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma (L-NN-MCL) with P53 Gene Re-arrangement/Mutation Is Highly Responsive to Rituximab/Ibrutinib Combination Therapy
Shahram Mori, Juan Varela, Steven C Goldstein, Daniel O Persky, Clinical Lymphoma, Myeloma, & Leukemia

Abstracts/Posters

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...
Juan Carlos Varela, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Authored Content

Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma (L-NN-MCL) with P53 Gene Re-arrangement/Mutation Is Highly Responsive to Rituximab/Ibrutinib Combination TherapyNovember 2018

Press Mentions

AdventHealth Launches First-of-Its-Kind Immunotherapy Treatment, Clinical Trial for Specific Blood Cancer PatientsJune 12th, 2020
Contigo Fund Gets $150,000 Grant from GileadOctober 17th, 2019
Vital £50,000 Boost for Dementia Research at St Andrews UniversitySeptember 30th, 2019
Join now to see all